Schorno Dean L, EVP, CFO, reported a transaction classified as exercise at RIGEL PHARMACEUTICALS INC involving 694.000000 shares for an estimated $8813.80. Reported holdings after the transaction were 79056.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
Form 4 relationship flags and nearby filing context
EVP & Chief Financial Officer
Includes 500 shares acquired under the Issuer's stock purchase plan.
These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the I…
The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Iss…
The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the Reporting Person's continuous service to the I…
The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2020, subject to the Reporting Person's continuous service to the I…
0 other filings
0 recent txs